Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Prostatic Neoplasms 15Prostatic Neoplasms, Castration-Resistant 2Pancreatic Neoplasms 2Ovarian Neoplasms 2Head and Neck Neoplasms 2Carcinoma, Transitional Cell 2Carcinoma, Renal Cell 2Breast Neoplasms 2Uveal Melanoma 1Urothelial Cancer 1Urologic Neoplasms 1Urogenital Neoplasms 1Urinary Bladder Neoplasms 1Sarcoma 1Prostatic Diseases 1Prostate Carcinoma Metastatic to the Bone 1Prostate Adenocarcinoma 1Penile Neoplasms 1Ovarian Diseases 1Neoplasms 1Neoplasm Metastasis 1Metastatic Hormone-sensitive Prostate Cancer (mHSPC) 1Metastatic Castration-sensitive Prostate Cancer 1Metastatic Castration-resistant Prostate Cancer (mCRPC) 1Metastatic Castration-resistant Prostate Cancer 1Mesothelioma 1Melanoma 1Lung Neoplasms 1Leukemia, Prolymphocytic, T-Cell 1Leukemia, Lymphocytic, Chronic, B-Cell 1

Interventions

niraparib 1luprolide acetate gel depot 1apalutamide 1Prednisone 1Androgen Antagonists 1Abiraterone Acetate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Metastatic Castration-sensitive Prostate Cancer × niraparib × Genitourinary × Clear all
NCT04497844 2026-06-05

AMPLITUDE

Janssen Research & Development, LLC

Phase 3 Active not recruiting
696 enrolled 15 charts 1 FDA
Genitourinary

Metastatic Castration-sensitive Prostate Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡